BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice President, Head of Corporate Development. He reports to Adi Mohanty, Co-Chief Executive Officer.

In his new role, Mr. Knight will oversee business development, portfolio strategy and strategic marketing. He brings more than 20 years of experience in creating portfolio value at publicly-traded companies including, Questcor Pharmaceuticals, Inc. and Elan Pharmaceuticals.

“Jim is a highly-accomplished professional with an extensive skill set and knowledge that is applicable immediately, as we have started reporting encouraging early clinical data on our key programs,” said Mr. Mohanty. “I’m confident that his track record of value creation, particularly during his time at Questcor, where he helped drive portfolio expansion that grew revenue from $150 million to more than $1 billion over a period of just four years, will assist us during this exciting juncture and help us create value for our shareholders.”

Most recently, Mr. Knight was the Vice President of Portfolio Strategy at Questcor from 2010 through 2014. Questcor was acquired by Mallinckrodt Pharmaceuticals for $5.6 billion in that year, and Mr. Knight stayed on for a transition and integration period through 2015. Prior to Questcor, Mr. Knight was at Elan Pharmaceuticals from 2001 to 2008, where he led a global strategic marketing team, working closely with collaborators at Biogen Inc. on the successful development and commercialization of Tysabri, a monoclonal antibody. He started his career in the research group at Biogen, before moving to sales and market analysis roles. Mr. Knight has a BS in Biology from the University of Massachusetts, Amherst and an MBA in High Technology from Northeastern University.

“I am excited to join the BioTime team,” said Mr. Knight. “The company’s proprietary pluripotent stem cells and HyStem delivery system have a growing body of data that support significant potential to deliver on revolutionary products. I feel confident that I can help accelerate the development of these products internally as well through appropriate partnerships.”

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005439/en/